Maya K. Leabman

8.0k total citations
33 papers, 2.0k citations indexed

About

Maya K. Leabman is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Clinical Biochemistry. According to data from OpenAlex, Maya K. Leabman has authored 33 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Clinical Biochemistry. Recurrent topics in Maya K. Leabman's work include Drug Transport and Resistance Mechanisms (15 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Metabolism and Genetic Disorders (9 papers). Maya K. Leabman is often cited by papers focused on Drug Transport and Resistance Mechanisms (15 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Metabolism and Genetic Disorders (9 papers). Maya K. Leabman collaborates with scholars based in United States, Switzerland and Australia. Maya K. Leabman's co-authors include Kathleen M. Giacomini, Mark J. Dresser, Thomas Urban, Susan J. Johns, Thomas E. Ferrin, Michiko Kawamoto, Conrad C. Huang, Joseph DeYoung, Ira Herskowitz and Doug Stryke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Oncology.

In The Last Decade

Maya K. Leabman

32 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maya K. Leabman United States	16	1.2k	675	442	334	278	33	2.0k
Shuiying Hu United States	32	1.7k 1.4×	1.3k 1.9×	406 0.9×	90 0.3×	127 0.5×	94	3.5k
Kari M. Morrissey United States	18	777 0.6×	512 0.8×	336 0.8×	62 0.2×	72 0.3×	25	1.5k
Tristan M. Sissung United States	30	1.4k 1.1×	1.2k 1.8×	296 0.7×	88 0.3×	101 0.4×	94	2.9k
Chee M. Ng United States	23	481 0.4×	503 0.7×	291 0.7×	401 1.2×	239 0.9×	57	1.7k
Ryan Owen United States	17	535 0.4×	719 1.1×	280 0.6×	32 0.1×	135 0.5×	35	2.4k
David Carlile United Kingdom	24	1.1k 0.9×	517 0.8×	126 0.3×	278 0.8×	266 1.0×	55	2.3k
Guangqing Xiao United States	20	555 0.5×	386 0.6×	308 0.7×	86 0.3×	83 0.3×	28	1.2k
Alain Munafo Switzerland	28	297 0.2×	340 0.5×	118 0.3×	221 0.7×	444 1.6×	63	1.9k
Kathleen Köck United States	21	991 0.8×	311 0.5×	427 1.0×	39 0.1×	92 0.3×	28	1.5k
Kouichi Kurose Japan	22	489 0.4×	661 1.0×	238 0.5×	51 0.2×	143 0.5×	54	2.0k

Countries citing papers authored by Maya K. Leabman

Since Specialization

Citations

This map shows the geographic impact of Maya K. Leabman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maya K. Leabman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maya K. Leabman more than expected).

Fields of papers citing papers by Maya K. Leabman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maya K. Leabman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maya K. Leabman. The network helps show where Maya K. Leabman may publish in the future.

Co-authorship network of co-authors of Maya K. Leabman

This figure shows the co-authorship network connecting the top 25 collaborators of Maya K. Leabman. A scholar is included among the top collaborators of Maya K. Leabman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maya K. Leabman. Maya K. Leabman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desbois, Mélanie, Kevin C. Hart, Thomas J. Matthew, et al.. (2024). Abstract 1899: Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models. Cancer Research. 84(6_Supplement). 1899–1899. 1 indexed citations

Nastoupil, Loretta J., Lihua E. Budde, Won Seog Kim, et al.. (2022). Abstract CT125: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas. Cancer Research. 82(12_Supplement). CT125–CT125. 1 indexed citations

Hart, Kevin C., Kathryn Logronio, Keyu Li, et al.. (2022). Abstract 4179: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing. Cancer Research. 82(12_Supplement). 4179–4179. 1 indexed citations

Budde, Elizabeth, Ajay K. Gopal, Won Seog Kim, et al.. (2021). A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. Blood. 138(Supplement 1). 132–132. 22 indexed citations

Deng, Rong, Daniela Bumbaca, Cinthia V. Pastuskovas, et al.. (2016). Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. mAbs. 8(3). 593–603. 153 indexed citations

Budha, Nageshwar, Maya K. Leabman, Jin Y. Jin, et al.. (2015). Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. The AAPS Journal. 17(4). 881–890. 15 indexed citations

Peng, Kun, Keyang Xu, Luna Liu, et al.. (2014). Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study. mAbs. 6(6). 1500–1508. 8 indexed citations

Gelzleichter, Thomas, Wendy Halpern, Amos Baruch, et al.. (2014). Combined Administration of RG7652, a Recombinant Human Monoclonal Antibody Against PCSK9, and Atorvastatin Does Not Result in Reduction of Immune Function. Toxicological Sciences. 140(2). 470–480. 6 indexed citations

Baruch, Amos, Maya K. Leabman, Nageshwar Budha, et al.. (2013). Abstract 12009: Effect of RG7652, a mAb Against PCSK9, on Apolipoprotein B, Oxidized LDL, Lipoprotein(a) and Lipoprotein-Associated Phospholipase A2 in Healthy Individuals With Elevated LDL-c. Circulation. 128. 2 indexed citations

10.

Leabman, Maya K., Y. Gloria Meng, Robert F. Kelley, et al.. (2013). Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs. 5(6). 896–903. 83 indexed citations

11.

Herbst, Roy S., Michael S. Gordon, Gregg Fine, et al.. (2013). A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.. Journal of Clinical Oncology. 31(15_suppl). 3000–3000. 157 indexed citations

12.

Chen, Ying, Shuanglian Li, Chaline Brown, et al.. (2009). Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenetics and Genomics. 19(7). 497–504. 174 indexed citations

13.

Urban, Thomas, Ronnie Sebro, Evan H. Hurowitz, et al.. (2005). Functional genomics of membrane transporters in human populations. Genome Research. 16(2). 223–230. 42 indexed citations

14.

Fujita, Tomoe, Thomas Urban, Maya K. Leabman, Kazumi Fujita, & Kathleen M. Giacomini. (2005). Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. Journal of Pharmaceutical Sciences. 95(1). 25–36. 99 indexed citations

15.

Fujita, Tomoe, Chaline Brown, Elaine J. Carlson, et al.. (2005). Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenetics and Genomics. 15(4). 201–209. 81 indexed citations

16.

Shu, Yan, Maya K. Leabman, Bo Feng, et al.. (2004). PharmGKB Update: III. Genetic Variants of SLC22A1, Solute Carrier Family 22 (Organic Cation Transporter), Member 1. Pharmacological Reviews. 56(2). 161–161. 4 indexed citations

17.

Leabman, Maya K. & Kathleen M. Giacomini. (2003). Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics. 13(9). 581–584. 54 indexed citations

18.

Dresser, Mark J., Guangqing Xiao, Maya K. Leabman, Andrew T. Gray, & Kathleen M. Giacomini. (2002). Interactions of n-Tetraalkylammonium Compounds and Biguanides with a Human Renal Organic Cation Transporter (hOCT2). Pharmaceutical Research. 19(8). 1244–1247. 68 indexed citations

19.

Leabman, Maya K., Conrad C. Huang, Michiko Kawamoto, et al.. (2002). Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 12(5). 395–405. 153 indexed citations

20.

Dresser, Mark J., Maya K. Leabman, & Kathleen M. Giacomini. (2001). Transporters involved in the elimination of drugs in the kidney: Organic anion transporters and organic cation transporters. Journal of Pharmaceutical Sciences. 90(4). 397–421. 209 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact